In 2024 it will have been 40 years since the DEA first moved to place MDMA in Schedule 1 of the Controlled Substances Act, asserting it held no therapeutic value, leading to the founding of the Multidisciplinary Association for Psychedelic Studies in 1986 by Rick Doblin. As 2023 comes to end we are anticipating the submission of a New Drug Application to the FDA by MAPS for MDMA-assisted therapy in the treatment of PTSD. Join Fluence for the final installment of of our free webinar series in 2023 as we discuss MDMA’s 40-year path to this moment in time—and what the next 40 years might bring—with MAPS founder Rick Doblin, PhD, Fluence trainer Chantelle Thomas, PhD and Fluence Co-Founder Ingmar Gorman, PhD.
The conversation will explore the final results of MAPS clinical trial exploring MDMA-assisted therapy for the treatment of PTSD, the hurdles still to clear, and implications for aspiring therapists and the importance of good drug education more broadly. This is a live and interactive webinar, and participants will have the opportunity to have questions answered during a Q&A period.
A recording of the webinar will be made available for those who register who are not able to attend the live event.